Skip to main content
TipRanks
Go Ultimate75% OFF

Harvard Apparatus Regenerative Technology (HRGN) AI Stock Analysis

106 Followers
HRGN

Harvard Apparatus Regenerative Technology

(Other OTC:HRGN)

Select Model
Rating:42Neutral
Price Target:$2.00â–²(5.26% Upside)
Action:reiterated
Date:11/14/26

The score reflects a high-risk, early-stage biotechnology company. The most significant factor is fragile financial health, marked by operating losses and cash burn despite initial revenue. A recent capital raise provides short-term relief but underscores the need for sustainable funding. Technicals show weak momentum, and the negative P/E confirms a lack of profitability.

Positive Factors
Revenue GrowthThe company is showing measurable recent top-line expansion, with revenue growth of 35.13% and TTM revenue above the latest annual figure. Continued sales growth could broaden the operating base and improve future earnings potential if management can convert that expansion into positive margins.
Negative Factors
Severe UnprofitabilityThe company has not demonstrated an economically sustainable operating model: modest revenue is accompanied by negative gross profit and very large losses. Persistent unprofitability limits internally generated funding, makes future financing more important, and leaves earnings power highly uncertain over the coming quarters.

Harvard Apparatus Regenerative Technology (HRGN) vs. SPDR S&P 500 ETF (SPY)

-60%-40%-20%0%20%40%HRGN+3.54%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$33.40M
Dividend Yield
―
Average Volume (3M)
3,754
Price to Earnings (P/E)
-5.0
Beta (1Y)
0.13
Revenue Growth
35.13%
EPS Growth
9.18%
Country
US
Employees
8
Sector
Consumer Defensive
Sector Strength
62
Industry
Biotechnology

Harvard Apparatus Regenerative Technology Business Overview & Revenue Model

Company Description

Harvard Apparatus Regenerative Technology Inc., a biotechnology firm currently conducting clinical trials, is dedicated to developing regenerative medical therapies. Its core mission involves addressing conditions affecting the gastrointestinal syste...

How the Company Makes Money

null

Harvard Apparatus Regenerative Technology Financial Statement Overview

Summary

Early-stage biotech with nascent revenue ($0.86M TTM) but negative gross margins and substantial operating losses ($6.4M TTM net loss). Low debt and positive equity are strengths, but cash burn ($2.8M TTM) and declining total assets present significant risks.

Income Statement

18Very Negative

Balance Sheet

35Negative

Cash Flow

25Negative
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Mar 2024Dec 2022Mar 2022
Income Statement
Total Revenue1.00M704.00K0000
Gross Profit46.00K58.00K-270.00K-24.00K00
EBITDA-6.33M-6.76M-8.16M-9.09M-5.92M-8.53M
Net Income-6.45M-6.87M-7.73M-9.02M-6.07M-7.98M
Balance Sheet
Total Assets3.17M2.68M4.44M2.61M2.40M1.87M
Cash, Cash Equivalents and Short-Term Investments1.85M1.35M2.49M432.00K1.24M1.24M
Total Debt116.00K199.00K294.00K48.00K147.00K169.00K
Total Liabilities2.65M1.62M1.22M968.00K1.41M4.89M
Stockholders Equity522.00K1.06M3.22M1.65M989.00K-3.03M
Cash Flow
Free Cash Flow-2.79M-3.83M-4.85M-6.95M-5.11M-2.63M
Operating Cash Flow-2.79M-3.83M-4.85M-6.94M-5.11M-2.63M
Investing Cash Flow000-11.00K-5,0000
Financing Cash Flow3.32M2.70M6.91M6.14M5.06M2.84M

Harvard Apparatus Regenerative Technology Technical Analysis

Technical Analysis SentimentNegative
Last Price1.90

Price Trends

50DMA2.12Negative
100DMA1.70Positive
200DMA1.63Positive

Market Momentum

MACD-0.04Positive
RSI43.21Neutral
STOCH22.40Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HRGN, the sentiment is Negative. The current price of 1.90 is below the 20-day moving average (MA) of 2.07, below the 50-day MA of 2.12, and above the 200-day MA of 1.63, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 43.21 is Neutral, neither overbought nor oversold. The STOCH value of 22.40 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HRGN.

Harvard Apparatus Regenerative Technology Risk Analysis

Harvard Apparatus Regenerative Technology disclosed 49 risk factors in its most recent earnings report. Harvard Apparatus Regenerative Technology reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks
1.Intellectual property rights do not necessarily address all potential threats to our competitive advantage.Q4, 2023
2.Cyber-attacks or other failures in telecommunications or information technology systems and deficiency in our, or those of third parties upon which we rely, cybersecurity could result in information theft, data corruption and significant disruption of our business operations.Q4, 2023

Harvard Apparatus Regenerative Technology Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

HRGN against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
LGVNLGVN45Neutral$6.81M-0.27-243.26%―-18.93%39.19%
HRGNHRGN42Neutral$38.18M-5.02-8830.14%―35.13%9.18%
CELUCELU39Underperform$20.09M-0.35142.25%―-58.14%47.25%
BRTXBRTX38Underperform$1.96M-0.06-423.84%―-8.47%25.62%
PLURPLUR27Underperform$14.95M-0.40147.42%―10.03%13.85%

* Consumer Defensive Sector Average

Performance Comparison

-50%0%50%HRGNPLURBRTXCELZCELULGVNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
HRGN and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
HRGNHarvard Apparatus Regenerative Technology Inc1.900.063.54%
PLURPluri Inc.1.04-2.52-70.79%
BRTXBiorestorative Therapies, Inc.1.42-27.18-95.03%
CELZCreative Medical Technology Holdings, Inc.0.52-2.39-82.13%
CELUCelularity Inc.0.62-1.07-63.37%
LGVNLongeveron Inc.2.14-4.01-65.18%

Harvard Apparatus Regenerative Technology Corporate Events

Business Operations and StrategyPrivate Placements and Financing

Harvard Apparatus Regenerative Technology Completes Equity Financing Round

Positive
Sep 14, 2026

On September 11, 2026, Harvard Apparatus Regenerative Technology, Inc. completed a private placement of 2,703,727 shares of common stock, raising $2,838,911 at a price of $1.05 per share from a group of investors. The transaction provided fresh equit...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026